Autres langues MINAPHARM Pharmaceuticals

Actions

MIPH

EGS380G1C011

Cours en clôture Egyptian Exchange Autres places de cotation 00:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
200,3 ^EGP	0,00%		0,00%	-8,00%

07/04	MINAPHARM Pharmaceuticals annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	MINAPHARM Pharmaceuticals annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	07/04
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	05/10/23
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	04/10/23
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	06/03/23
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)	06/03/23
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	30/11/22
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa	29/11/22
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved	29/11/22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/11/22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	02/06/22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	30/11/21
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	31/08/21
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021	12/08/21
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021	16/06/21
ProBioGen AG and MINAPHARM Pharmaceuticals Incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company	27/05/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MINAPHARM Pharmaceuticals

Actions

MIPH

EGS380G1C011

Autres langues

Filtres